Table 3.

Analysis of SLN metastases from recent studies

Author, year	N (with SLN assessment)	Macro-metastasis	Micro-metastasis	ITC (only)	Total LN positive
Holloway et al 2016 [67]	119	14 (12%)	10 (8.4%)	12 (10%)	36 (30%)
Touhami et al 2015 [55]	268	24 (9%)	7 (2.6%)	12 (4.5%)	43 (16%)
Desai et al 2014 [41] *	103	5 (4.9%)	5 (4.9%)	–	10 (9.7%)
Raimond et al 2014 [69]	136	7 (5%)	15 (11%)	–	22 (16%)
Kim 2013 [45] **	508	35 (7%)	4 (0.8%)	19 (3.7%)	64 (13%)
Ballester et al 2011 [30]	111	8 (7%)	7 (6.3%)	1 (0.9%)	16 (14%)
OVERALL	1,245	93 (7.5%)	48 (3.9%)	44 (3.5%)	185 (14.9%)

^*IHC positive only (no description of size of metastasis in the SLN)

^**includes 6 patients with positive non-SLN

Abbreviations: SLN = sentinel lymph node; N = number of patients; ITC = isolated tumor cells; LN = lymph node